Research · Source update
ACHIEVE-5 studies Foundayo alongside basal insulin
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly published findings from a diabetes study involving adults already taking insulin glargine. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly published findings from a diabetes study involving adults already taking insulin glargine. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results, dated 2026-06-08.
What did the source report?
The company reported additional HbA1c reductions with orforglipron relative to placebo at 40 weeks. ACHIEVE-5 examined adding orforglipron to treatment that already included basal insulin glargine.
How should the results be interpreted?
People using insulin need individualized low-glucose monitoring and medication decisions; trial results are not dosing instructions. Lilly reported HbA1c reductions up to 2.1 percentage points versus about 0.8 for placebo at 40 weeks; background insulin and monitoring remain clinically important.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
Combination regimens require clinical oversight. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
Combination regimens require clinical oversight.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-06-08. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results ↗
Source event or update: 2026-06-08. Our interpretation is educational and does not replace medical or insurance advice.